T-DXd
Breast Cancer
A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases
André F, Cortés J, Curigliano G, et al.
Ann Oncol. 2024;35(12):1169-1180. doi: 10.1016/j.annonc.2024.08.2347.
T-DXd
Breast Cancer
Trastuzumab deruxtecan for the treatment of patients with HER2-positive breast cancer with brain and/or leptomeningeal metastases: an updated overall survival analysis using data from a multicenter retrospective study (ROSET-BM)
Nakayama T, Niikura N, Yamanaka T, et al.
Breast Cancer. 2024;31(6):1184. doi: 10.1007/s12282-024-01632-z.
T-DXd
Tumor-agnostic
Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: Post hoc analysis of DESTINY-PanTumor02
Oaknin A, Lee J-Y, Makker V, et al.
Adv Ther. 2024;41(11):4125-4139. doi: 10.1007/s12325-024-02975-x.
T-DXd
Breast Cancer
A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B)
Sakai H, Tsurutani J, Ozaki Y, et al.
Ann Oncol. 2025;36(1):31-42. doi: 10.1016/j.annonc.2024.09.001.
T-DXd
Breast Cancer
Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer
Bardia A, Hu X, Dent R, et al.
N Engl J Med. 2024;391(22):2110-2122. doi: 10.1056/NEJMoa2407086
Dato-DXd
Breast Cancer
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: The sequential multiple assignment randomized I-SPY2.2 phase 2 trial
Shatsky RA, Trivedi MS, Yau C, et al.
Nat Med. 2024;30(12):3737-3747. doi: 10.1038/s41591-024-03267-1.
Other/Multi
Other/Multi
Decoding clinical trial jargon: Helping people understand the efficacy end points used in cancer trials
Henley M, DeCotiis G, FitzGibbon H, Singhi EK
Future Oncol. 2025;21(1):11-14. doi: 10.1080/14796694.2024.2433411.
Dato-DXd
Breast Cancer
TROPION-Breast04: A randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer
McArthur HL, Tolaney SM, Dent R, et al.
Ther Adv Med Oncol. 2025 Feb;17:17588359251316176. doi: 10.1177/17588359251316176.
Edoxaban
Cardiovascular - VTE
Treatment of venous thromboembolism with edoxaban over 18 months: Results from ETNA-VTE Europe
Agnelli G, Hoffmann U, Hainaut P, et al.
Thromb Haemost. 2025. doi: 10.1055/a-2497-4089.
Edoxaban
Cardiovascular - AF
Epistaxis versus nonepistaxis bleeding in anticoagulated patients with atrial fibrillation: Results from the ENGAGE AF-TIMI 48 trial
Semco RS, Bergmark RW, Murphy SA, et al.
J Am Heart Assoc. 2025 Jan;14(2):e031434. doi: 10.1161/JAHA.123.031434.